Esperion Therapeutics (ESPR) Operating Expenses (2012 - 2026)

Esperion Therapeutics' Operating Expenses history runs 15 years deep, the most recent figure standing at $86.7 million for Q1 2026.

• Quarterly Operating Expenses changed 0.47% year-over-year to $86.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.8 million (down 56.99% YoY) and the FY2025 annual result came in at $129.2 million, down 53.5% from the prior year.
• Operating Expenses was $86.7 million for Q1 2026 at Esperion Therapeutics, up from -$130.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $97.3 million in Q3 2025 and bottomed at -$130.4 million in Q4 2025.
• A 5-year average of $60.0 million and a median of $71.2 million in 2022 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 43.76% in 2025, while the deepest fall reached 277.37% in 2025.
• Esperion Therapeutics' Operating Expenses stood at $61.3 million in 2022, then climbed by 21.66% to $74.6 million in 2023, then dropped by 1.45% to $73.5 million in 2024, then sank by 277.37% to -$130.4 million in 2025, then jumped by 166.46% to $86.7 million in 2026.
• Business Quant data shows ESPR's Operating Expenses at $86.7 million in Q1 2026, -$130.4 million in Q4 2025, and $97.3 million in Q3 2025.